Abstract
.
Highlights
Dear Editor, Corticosteroids are very accessible drugs, and nowadays, they have been the mainstay of treatment for severe COVID-19
We have recently received a considerable number of COVID-19 patients that began corticosteroid therapy in a mild-moderate disease at our tertiary referral center
Since June 2020, corticosteroids are an option of treatment because of the recovery trial results [1], about low doses of dexamethasone, which reduced deaths up to one-third in ventilated patients and one-fifth in other patients receiving oxygen
Summary
Three days after close contact with a COVID-19 positive relative, he was tested with nasopharyngeal swap RT-PCR and confirmed a SARSCoV-2 infection He was isolated at home by medical advice. By a primary care physician's recommendation, he started dexamethasone 16 mg intramuscularly daily Six days later, he began with a fever, shortness of breath, and cough with purulent sputum; because of that, he was brought by relatives to seek medical attention. Biochemical data and completed blood count showed the following relevant findings: Glucose, 332 mg/dL; DHL, 530 mg/dL; high-sensitive Creactive protein (CRP), 25 mg/L; procalcitonin, 12 ng/mL; leukocytes, 17.6×109/L; neutrophils, 15.2×109/L; lymphocytes, 1.4×109/L. He evolved to acute respiratory distress syndrome that required invasive ventilation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
